Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.
1:22-cv-00335
Overview
Parties
Amicus
Genevant Sciences GmbH NPE (Individual / Inventor)
Represented By
1 Attorneys ListedShaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
Arbutus Biopharma Corporation NPE (Individual / Inventor)
Represented By
1 Attorneys ListedShaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
Defendant
ModernaTX, Inc. Operating Company
Represented By
6 Attorneys ListedCooley LLP
10265 Science Center Drive, San Diego, CA 92121
Cooley LLP
30 S. 9th Street, 7th Floor
Farnan LLP
919 North Market Street, 12th Floor
Farnan LLP
919 North Market Street, 12th Floor
Counter Claimant
Moderna US, Inc. Operating Company
Represented By
6 Attorneys ListedCooley LLP
10265 Science Center Drive, San Diego, CA 92121
Cooley LLP
30 S. 9th Street, 7th Floor
Farnan LLP
919 North Market Street, 12th Floor
Farnan LLP
919 North Market Street, 12th Floor
Moderna, Inc. Operating Company
Represented By
19 Attorneys ListedCooley LLP
10265 Science Center Drive, San Diego, CA 92121
Cooley LLP
30 S. 9th Street, 7th Floor
Farnan LLP
919 North Market Street, 12th Floor
Farnan LLP
919 North Market Street, 12th Floor
Counter Defendant
Alnylam Pharmaceuticals, Inc. Operating Company
Represented By
8 Attorneys ListedMcDermott Will & Emery LLP
The Nemours Building, 1007 North Orange Street
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 17 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → |
Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.
Alnylam Pharmaceuticals, Inc. v. Pfizer Inc.
Alnylam Pharmaceuticals, Inc. v. Pfizer Inc.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US11246933
Biodegradable lipids for the delivery of active agents
|
Filed: 2021-04-29
Issued: 2022-02-15
|
Active (14.4 yrs remaining)
Expires: 2041-04-29
|
|
|
US11382979
Biodegradable lipids for the delivery of active agents
|
Filed: 2021-12-17
Issued: 2022-07-12
|
Active (15.1 yrs remaining)
Expires: 2041-12-17
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term — No obviousness-type double patenting noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
57
Dispositive
14
Granted
1
Denied
7
Pending / Review
34
Motions by Category
Key Dispositive Motions & Rulings